Open AccessStock price performance of pharmaceutical companies: pre-vaccine COVID-19 - post-vaccine COVID-19
Author(s) -
Henry Daniel Vera Ramírez,
Ferly Antonio Valencia Serna
Publication year - 2022
Publication title -
revista de estudios empresariales
Language(s) - English
Resource type - Journals
eISSN - 1988-9046
pISSN - 0213-8964
DOI - 10.17561/ree.n1.2022.6638
Subject(s) - covid-19 , stock (firearms) , econometrics , earnings , business , regression analysis , economics , financial economics , actuarial science , virology , accounting , statistics , medicine , mathematics , engineering , infectious disease (medical specialty) , mechanical engineering , disease , outbreak , pathology
This paper performs an analysis of the behaviour of the shares of the main pharmaceutical companies that research to obtain vaccines with a high degree of efficacy for COVID-19. A multiple regression econometric model is proposed, which relates stock prices to the impact of vaccine development on stock prices, including a dummy variable -over the time series- in the analysis. The results suggest significant associations between some pharmaceutical companies that developed vaccines in record time in the period analysed and an impact on the sector’s earnings performance.